HLB "Reconfirmation of the Excellent Therapeutic Effect of Rivoceranib at ESMO GI"

[Asia Economy Reporter Hyunseok Yoo] As the ESMO GI 2021, a world-renowned gastrointestinal tumor conference organized by the European Society for Medical Oncology, is held online, HL Biopharma announced on the 30th that multiple cases of Complete Response have been revealed for rivoceranib (Chinese name Apatinib), for which it holds global rights.

According to the abstracts published on the ESMO website, four studies related to rivoceranib conducted in China are scheduled to be presented in poster form.

At the Affiliated Hospital of Hebei University in China, 50 colorectal cancer patients were treated with a combination of rivoceranib and neoadjuvant chemotherapy followed by surgery. Clinical results showed complete response in 4 patients, with an objective response rate (ORR) of 72.0% and a disease control rate (DCR) of 94%. No severe adverse events (Grade 3) were observed except for mild symptoms, confirming high significance in the treatment of colorectal cancer patients.

In the esophageal cancer field, where complete response was previously announced at ASCO GI in January, another complete response was observed. At Dezhou People's Hospital in China, 50 patients with advanced esophageal cancer, who were inoperable and had no suitable treatment options after first-line therapy, were treated with rivoceranib monotherapy. One patient showed complete response, with an ORR of 16.7%, DCR of 64.3%, median progression-free survival (mPFS) of 8.7 months, and median overall survival (mOS) of 10.9 months, demonstrating the superior efficacy of rivoceranib for esophageal cancer.

Additionally, in a Phase 3 clinical trial involving 180 HER2-negative gastroesophageal junction cancer patients conducted at Hebei Medical University, a complete response rate of 33.3% was achieved along with an ORR of 60% and DCR of 96.7%. Furthermore, in nonclinical animal studies combining Taseva (erlotinib) and rivoceranib, it was confirmed that in animal models with EGFR (epidermal growth factor receptor) mutations, the combination of EGFR and VEGFR (vascular endothelial growth factor receptor) inhibitors showed significantly superior tumor growth inhibition compared to monotherapy.

While the broad efficacy of rivoceranib is being confirmed through hundreds of papers annually, complete response cases have been reported in various cancers including lung cancer, stomach cancer, esophageal cancer, lymphoma, and colorectal cancer. Moreover, multiple clinical results on this specific drug are being consecutively presented at prestigious conferences such as ASCO and ESMO, which is considered quite exceptional.

This content was produced with the assistance of AI translation services.